Navigation Links
U.S. Approves New Stem Cell Lines for Publicly Funded Research

13 added batches now available, many more to come, NIH director says,,

WEDNESDAY, Dec. 2 (HealthDay News) -- Thirteen stem cell lines have been added to the pool that scientists can use for taxpayer-funded research, and many more such lines will soon be made available, U.S. health officials announced Wednesday.

These are the first additional embryonic stem cell lines approved for research funded by the U.S. National Institutes of Health (NIH) since President Barack Obama last spring lifted restrictions on stem cell research that were imposed eight years ago by then-President George W. Bush.

"With these [lines] now becoming available for federally funded researchers, we believe it will speed up the process of investigating ways in which this remarkable new area of developmental biology can be explored," NIH director Dr. Francis S. Collins said during an afternoon teleconference Wednesday.

"The field has been waiting with bated breath for this announcement," one expert, Dr George Daley of Children's Hospital Boston, told the Associated Press. Eleven of the 13 stem cell lines approved Wednesday were developed at Children's, Collins noted, while the other two come from Rockefeller University in New York City.

Collins noted that over the past eight years, hundreds of embryonic stem cell lines have been created using private funds. "Many of them with more favorable characteristics for research purposes than the original ones approved by President Bush," he said.

Citing ethical issues, the Bush administration had limited federally funded research to about 21 stem cell lines already in existence in August 2001. That decision ignited a firestorm of controversy between those who advocated that human embryos should not be tampered with and those who viewed stem cell research as a potential pathway to curing a host of diseases.

Currently, 96 more human embryonic stem cell lines are under review to see if they meet the criteria for NIH-funded research, Collins said. Only one of the Bush-approved stem cell lines is among the 96 under consideration.

Recommendations to approve or reject 20 of these lines is expected on Friday, the NIH director said.

NIH policy still calls for new embryonic stem cell lines to be developed without taxpayer funding. "There is still a ban against the creation of new stem cell lines with federal funds," Collins stressed.

All the stem cell lines NIH is considering are derived from embryos left over from in vitro fertilization. These embryos would have been discarded, but the donors gave permission for them to be used in research, Collins noted.

At present, 31 NIH research grants, worth $21 million, are on hold, awaiting approval of these stem cell lines. With the approval of the 13 lines, researchers can begin to look at these lines to see if they are appropriate for their projects, Collins said.

Those projects include efforts to grow heart muscle, neurological stem cells and neurons. Other research is focusing on ways to produce more stem cells so they can be available in greater quantities to researchers, he said.

Embryonic stem cells are thought to be especially useful to medical science because they can be manipulated to become any type of body cell. Scientists hope to use these cells to create replacement tissues to treat a variety of diseases, such as diabetes, Parkinson's, spinal cord injuries and Alzheimer's disease.

"It is exciting to be able to say that -- after what has clearly been a time of some frustration on the part of the scientific community's inability to gain access with federal funds to cell lines that investigators wish to utilize -- that is now changing," Collins said.

More information

For more information on stem cells, visit the U.S. National Institutes of Health .

SOURCES: Dec. 2, 2009, teleconference with: Francis S. Collins, M.D., Ph.D., director, U.S. National Institutes of Health; Associated Press

Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... PRMA Plastic ... November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , ... wake up every day excited to rebuild lives and it’s an honor to have ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings Final ... ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, ... giving users limitless opportunities to stylize and create designs quickly and easily, all ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
Breaking Medicine Technology: